Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

BACKGROUND: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavelka, Karel, Kivitz, Alan, Dokoupilova, Eva, Blanco, Ricardo, Maradiaga, Marco, Tahir, Hasan, Pricop, Luminita, Andersson, Mats, Readie, Aimee, Porter, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741872/
https://www.ncbi.nlm.nih.gov/pubmed/29273067
http://dx.doi.org/10.1186/s13075-017-1490-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741872/
https://www.ncbi.nlm.nih.gov/pubmed/29273067
http://dx.doi.org/10.1186/s13075-017-1490-y

Ejemplares similares